Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.523 USD | +1.00% | +4.39% | -1.99% |
03-22 | Sangamo Therapeutics Prices $24 Million Registered Direct Offering | MT |
03-14 | Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 4.01 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-1.99% | 107M | C | ||
-2.70% | 103B | B+ | ||
+1.67% | 95.28B | B+ | ||
+1.75% | 22.15B | B | ||
-15.45% | 21.02B | B+ | ||
-8.58% | 18.15B | A- | ||
-41.01% | 16.73B | A- | ||
-13.38% | 16.05B | B | ||
+4.03% | 13.68B | C+ | ||
+34.74% | 12.17B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SGMO Stock
- Ratings Sangamo Therapeutics, Inc.